دورية أكاديمية
68 Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy.
| العنوان: | 68 Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy. |
|---|---|
| المؤلفون: | Haidar M; Department of Diagnostic Radiology, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon. mh209@aub.edu.lb., Abi-Ghanem AS; Department of Diagnostic Radiology, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Moukaddam H; Department of Diagnostic Radiology, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Jebai ME; Department of Diagnostic Radiology, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Al Zakleet S; Department of Diagnostic Radiology, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Al Rayess S; Department of Diagnostic Radiology, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Akkawi AR; Department of Internal Medicine, University of Kansas School of Medicine-Wichita, Wichita, KS, USA., Kassas M; Department of Diagnostic Radiology, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Tamim H; Clinical Research Institute, American University of Beirut, Beirut, Lebanon., Hajj AE; Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon., Estrada-Lobato E; Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria., Osman MM; Division of Nuclear Medicine, Department of Radiology, Saint Louis University Hospital, St. Louis, MO, 63110, USA., Shamseddine A; Department of Internal Medicine, Division of Hematology and Oncology, Faculty of Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon. |
| المصدر: | Scientific reports [Sci Rep] 2022 Nov 28; Vol. 12 (1), pp. 20500. Date of Electronic Publication: 2022 Nov 28. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
| مواضيع طبية MeSH: | Positron Emission Tomography Computed Tomography* , Prostatic Neoplasms*/diagnostic imaging , Prostatic Neoplasms*/therapy, Male ; Humans ; Androgen Antagonists ; Prospective Studies ; Prostate-Specific Antigen ; Chronic Disease |
| مستخلص: | Biochemical recurrence (BCR) of prostate cancer (PCa) occurs in about 25% of patients treated with radical prostatectomy (RP) and up to 45% in patients who receive external beam radiotherapy (RT). Early diagnosis of PCa recurrence is of high importance for successful salvage therapy. The aim of the present study is to analyze the efficacy of 68 Ga-PSMA PET/CT in detecting the presence of local and/or systemic disease in patients with a history of PCa who have BCR. A total of 52 PCa patients with BCR referred for 68 Ga-PSMA PET/CT were recruited from the American University of Beirut Medical Center between November 2017 and December 2019. We compared the performance of PSMA PET/CT to the results and clinical factors based on follow up: PSA, PSA kinetics, primary treatment, and Gleason score. The relationship between the PET/CT findings and clinical indicators of disease were assessed by univariate and multivariate logistic regression. From a total of 52 patients, 34 (65.4%) had positive PSMA-PET/CT scans. Among those, 8/34 (23.5%) received primary RT. For all patients with a positive PSMA-PET: the detection rate was 2/4 (50%) for PSA < 0.2, 5/10 (50%) for PSA 0.2-0.49, 3/6 (50%) for PSA 0.5-0.99, 6/12 (50%) for PSA 1-1.99, 8/9 (88.9%) for PSA 2-3.99, and 10/11 (90.9%) for PSA 4-10.PSMA-PET/CT positivity was significantly associated with PSA level at time of PET scan, PSA doubling time, Gleason score and TNM staging. However, it did not show a significant correlation with radiotherapy as primary treatment, ongoing androgen deprivation therapy (ADT), time to relapse, and initial PSA before therapy. In our single center prospective trial, 68 Ga-PSMA PET/CT successfully detected the recurrence of PCa in patients with BCR. Scan positivity was significantly associated with PSA level at time of PET scan, PSA doubling time, Gleason score, and TNM staging. PSMA- PET/CT is a highly promising modality in the work up of patients with PCa in the setting of BCR for earlier detection of disease recurrence. (© 2022. The Author(s).) |
| References: | Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94. (PMID: 25975367) J Nucl Med. 2017 Dec;58(12):1956-1961. (PMID: 28522741) J Nucl Med. 2015 Aug;56(8):1185-90. (PMID: 26112024) Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):960-968. (PMID: 28280856) JAMA Oncol. 2019 Jun 01;5(6):856-863. (PMID: 30920593) Eur Urol. 2016 Mar;69(3):393-6. (PMID: 26116958) Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20. (PMID: 24072344) J Urol. 2008 Mar;179(3):906-10; discussion 910. (PMID: 18207194) Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1288-99. (PMID: 26753602) Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):397-403. (PMID: 26563121) J Cell Biochem. 2004 Feb 15;91(3):528-39. (PMID: 14755683) Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):197-209. (PMID: 25411132) Cancers (Basel). 2019 May 23;11(5):. (PMID: 31126071) Clin Transl Oncol. 2021 Feb;23(2):364-371. (PMID: 32602076) Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):701-709. (PMID: 29280465) Prostate. 2015 Dec;75(16):1934-40. (PMID: 26356236) J Clin Oncol. 2005 Oct 1;23(28):7005-12. (PMID: 16192588) Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52. (PMID: 11483335) Eur Urol. 2014 Feb;65(2):467-79. (PMID: 24321502) Int Braz J Urol. 2018 Sep-Oct;44(5):892-899. (PMID: 30088720) Clin Cancer Res. 2021 Jul 1;27(13):3674-3682. (PMID: 33622706) J Urol. 2019 Aug;202(2):231-240. (PMID: 30829130) Eur Urol. 2016 Dec;70(6):926-937. (PMID: 27363387) Urol Int. 2017;99(4):406-413. (PMID: 29020683) World J Surg. 2006 Apr;30(4):628-36. (PMID: 16555021) Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):34-41. (PMID: 26404016) J Nucl Med. 2014 Sep;55(9):1424-9. (PMID: 24935990) J Nucl Med. 2015 May;56(5):668-74. (PMID: 25791990) J Nucl Med. 2022 Feb;63(2):240-247. (PMID: 34215674) Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2222-31. (PMID: 25182750) J Nucl Med. 2022 Jan;63(1):59-68. (PMID: 34593595) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Front Oncol. 2018 Dec 20;8:623. (PMID: 30619757) J Nucl Med. 2017 Jun;58(6):947-952. (PMID: 27908968) Sci Rep. 2022 Jul 22;12(1):12589. (PMID: 35869124) |
| المشرفين على المادة: | 0 (gallium 68 PSMA-11) 0 (Androgen Antagonists) EC 3.4.21.77 (Prostate-Specific Antigen) |
| تواريخ الأحداث: | Date Created: 20221128 Date Completed: 20221130 Latest Revision: 20230110 |
| رمز التحديث: | 20230111 |
| مُعرف محوري في PubMed: | PMC9705359 |
| DOI: | 10.1038/s41598-022-24688-3 |
| PMID: | 36443430 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2045-2322 |
|---|---|
| DOI: | 10.1038/s41598-022-24688-3 |